1. Home
  2. ASPI vs PRTA Comparison

ASPI vs PRTA Comparison

Compare ASPI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ASP Isotopes Inc.

ASPI

ASP Isotopes Inc.

HOLD

Current Price

$4.92

Market Cap

637.1M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.84

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASPI
PRTA
Founded
2021
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
637.1M
539.9M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
ASPI
PRTA
Price
$4.92
$10.84
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$12.00
$19.00
AVG Volume (30 Days)
4.0M
403.1K
Earning Date
04-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$23,849,000.00
$814,000.00
Revenue This Year
$68.41
$1,111.38
Revenue Next Year
$126.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
475.48
N/A
52 Week Low
$3.92
$4.32
52 Week High
$14.49
$11.69

Technical Indicators

Market Signals
Indicator
ASPI
PRTA
Relative Strength Index (RSI) 47.63 58.19
Support Level $3.98 $9.69
Resistance Level $5.90 $10.90
Average True Range (ATR) 0.51 0.39
MACD 0.04 0.01
Stochastic Oscillator 43.38 50.36

Price Performance

Historical Comparison
ASPI
PRTA

About ASPI ASP Isotopes Inc.

ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: